autologous anti-psca-car-4-1bb/tcrzeta-cd19t-expressing t-lymphocytes
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 23, 2019 (NCT03873805)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05805371 | Phase 1 | Dec 30, 2023 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03873805 | Phase 1 | May 23, 2019 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 2 | 2 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1